Recent Advances in Targeted Therapies for Infantile Hemangiomas
Tiantian Liang,Xianbin Liu,Yujun Tong,Qian Ding,Min Yang,Hong Ning
DOI: https://doi.org/10.2147/ijn.s463119
IF: 7.033
2024-06-20
International Journal of Nanomedicine
Abstract:Tiantian Liang, 1, &ast Xianbin Liu, 1, &ast Yujun Tong, 2 Qian Ding, 3 Min Yang, 1 Hong Ning 1 1 Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, People's Republic of China; 2 Department of Breast Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, People's Republic of China; 3 Department of Clinical Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hong Ning; Min Yang, Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 12, Changjia Alley, Jingzhong Street, Mianyang, Sichuan, 621000, People's Republic of China, Email ; Targeted therapy for infantile hemangiomas (IHs) has been extensively studied as they can concentrate drugs, increase therapeutic efficacy and reduce drug dosage. Meanwhile, they can extend drug release times, enhance drug stability, decrease dosing frequency, and improve patient compliance. Moreover, carriers made from biocompatible materials reduced drug immunogenicity, minimizing adverse reactions. However, current targeted formulations still face numerous challenges such as the non-absolute safety of carrier materials; the need to further increase drug loading capacity; the limitation of animal hemangioma models in fully replicating the biological properties of human infantile hemangiomas; the establishment of models for deep-seated hemangiomas with high incidence rates; and the development of more specific targets or markers. In this review, we provided a brief overview of the characteristics of IHs and summarized the past decade's advances, advantages, and targeting strategies of targeted drug delivery systems for IHs and discussed their applications in the treatment of IHs. Furthermore, the goal is to provide a reference for further research and application in this field. Keywords: targeting, targeted therapies, infantile hemangiomas, drug delivery systems, nanoparticle IHs are benign tumors characterized by abnormal proliferation of endothelial cells and extensive vascular growth within the hemangioma in infants and young children. 1 The global incidence of IHs is approximately 4% to 10%. 2 Most IHs do not require special treatment and resolve with infant growth, but 10% to 15% of patients will have high-risk complications, such as possible malformations, major structural obstructions, persistent ulcers, organ dysfunction, disfigurement, and even life-threatening conditions. 3,4 IHs with high-risk complications not only affect the external appearance, anatomical structures, and physiological functions of the body but also impose significant psychological stress and may lead to psychological disorders in affected patients. Therefore, active intervention is required, and the earlier the better, to intervene at the source and prevent irreversible physical and psychological damage to infants and young children. Currently, the primary treatment modality for IHs is pharmacotherapy, with secondary treatment options including non-pharmacological approaches such as laser therapy, surgical excision, and cryotherapy. 5,6 However, laser therapy can easily cause pigmentation, blistering, and even tissue necrosis. The timing of surgical excision is crucial, as the scars produced by surgery ares usually suboptimal in children over 1.5 years old. 7 Additionally, the abundant and intricate vasculatures surrounding the hemangioma result in a high risk of bleeding during surgery. Also, cryotherapy has a narrow range of indications. The β-receptor blocker propranolol is the only drug approved by the United States Food and Drug Administration (FDA) for the treatment of IHs. 8 The oral liquid formulation of propranolol suitable for pediatric patients is currently available on the market. Meanwhile, safer β-receptor blockers, such as Nadolol and Atenolol, are currently undergoing clinical trials. 9,10 However, the β-receptor blockers may have adverse effects including sleep disturbances, hypoglycemia, hypotension, bradycardia, and bronchospasm. 11–13 These adverse effects could potentially cause secondary harm to infants and young children. Therefore, close monitoring of the patient's blood pressure and heart rate is necessary during clinical use. To overcome these challenges, researchers are continuously exploring new drug delivery methods and materials to safely and efficiently deliver drugs to the -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology